Pills

This is the text extract for Schedule Update - effective 1 November 2013, browse documents here.


Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 November 2013

Cumulative for September, October and November 2013


Contents

Summary of PHARMAC decisions effective 1 November 2013 ....................... 3 Have a problem with a medicine or medical device we fund? ...................... 4 Mycophenolate mofetil price changes .......................................................... 4 Apresoline, Tofranil and Ludiomil – no longer section 29 .............................. 5 Delay in listing of Amoxycillin ....................................................................... 5 Carbimazole – stock shortage ....................................................................... 5 Pramipexole – stock shortage ........................................................................ 5 Ondansetron 4 mg ODT – stock shortage...................................................... 5 Prednisone tab 1 mg – re-supply ................................................................... 6 News in brief ................................................................................................. 6 Tender News .................................................................................................. 7 Looking Forward ........................................................................................... 7 Sole Subsidised Supply products cumulative to November 2013 .................. 8 New Listings ................................................................................................ 19 Changes to Restrictions, Chemical Names and Presentations ...................... 23 Changes to Subsidy and Manufacturer’s Price............................................. 29 Changes to General Rules............................................................................ 32 Changes to Brand Name ............................................................................. 33 Changes to Section I ................................................................................... 33 Delisted Items ............................................................................................. 34 Items to be Delisted .................................................................................... 37 Index ........................................................................................................... 39

2


Summary of PHARMAC decisions

EFFECTIVE 1 NOVEMBER 2013 New listings (page 19) • Lactulose (Laevolac) oral liq 10 g per 15 ml, 500 ml • Cetomacrogol with glycerol (Pharmacy Health Sorbolene with Glycerin) crm 90% with glycerol 10%, 1,000 g OP • Paroxetine hydrochloride (Loxamine) tab 20 mg – 90 tab pack size • Ondansetron (Onrex) tab 4 mg and 8 mg • Alprazolam (Xanax) tab 250 mcg, 500 mcg and 1 mg • Methotrexate (Methotrexate Sandoz) inj 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg pre-filled syringe • Salbutamol (Ventolin) oral liq 400 mcg per ml, 150 ml • Oral feed (powder) (Ensure) powder (vanilla) 850 g OP – Special Authority – Hospital Pharmacy [HP3] Changes to restrictions, chemical names and presentation (pages 23-24) • Hydrazaline hydrochloride (Apresoline) inj 20 mg ampoule – Removal of S29 • Valganciclovir (Valcyte) tab 450 mg – Amendment of Special Authority criteria • Maprotiline hydrochloride (Ludiomil) tab 75 mg – Removal of S29 • Imipramine hydrochloride (Tofranil) tab 10 mg – Removal of S29 • Salbutamol (Salapin, Ventolin) oral liq 400 mcg per ml – Change in presentation description Decreased subsidy (page 29) • Alprazolam (Arrow-Alprazolam) tab 250 mcg and 1 mg • Mycophenolate mofetil (Ceptolate) tab 500 mg and cap 250 mg; (Myaccord) tab 500 mg and cap 250 mg

3


4 Pharmaceutical Schedule - Update News

Have a problem with a medicine or medical device we fund?

PHARMAC welcomes feedback, including complaints about any medicine we fund. We want to know when we get things right and when we could do better. We particularly want to know about problems with access or compliance, such as when a product is in short supply or you have difficulty interpreting our rules. Some issues should also be reported to other organisations. These include: Quality complaints should be reported to the importer or supplier in the first instance. A quality complaint could include such issues as: a label that is easily smudged or doesn’t stay on the container, a tablet that won’t break evenly along a score line, inconsistent viscosity of a liquid medicine. Quality complaints may also be reported to

Medsafe especially if the issue is serious. Medicine adverse reactions should be reported to the Centre for Adverse Reactions Monitoring (CARM). This includes side effects and/or lack of efficacy of a medicine as a result of a brand change. Medical device adverse reactions should be reported to Medsafe. A form is available on the Medsafe website. http://www.medsafe.govt. nz/regulatory/devicesnew/safety.asp

Mycophenolate mofetil price changes

From 1 February 2014, the Cellcept brand will be the sole subsidised brand of mycophenolate mofetil 250 mg capsules and 500 mg tablets. The Myaccord and Ceptolate brands will have a subsidy reduction from 1 November 2013 and be delisted from 1 February 2014.


Pharmaceutical Schedule - Update News

5

Apresoline, Tofranil and Ludiomil – no longer section 29

Apresoline (hydralazine hydrochloride) 20 mg injection, Tofranil (imipramine hydrochloride) 10 mg tablets, and Ludiomil (maprotiline hydrochloride) 25 mg tablets are no longer being supplied under section 29 of the Medicines Act 1981, These products are now registered. The section 29 symbol on these products will be removed from 1 November 2013.

Delay in listing of Amoxycillin

Apo-Amoxi (amoxycillin) 250 mg and 500 mg capsules, supplied by Apotex NZ Ltd, was scheduled to be listed from 1 November 2013. This has been delayed until further notice and the Alphamox brand, supplied by Mylan NZ Ltd, will remain listed until notified. We will continue to keep you informed of the amended listing date.

Carbimazole – stock shortage

AFT have advised that following the closure of the API manufacturing plant for NeoMercazole, (carbimazole), that there is a global shortage of stock. We are working with AFT to identify alternative suppliers, however an out-of-stock may occur. Patients may need to see their prescriber if stock is unavailable.

Pramipexole – stock shortage

PHARMAC is working with an alternative supplier of pramipexole, following Dr Reddy’s discontinuation of its brand. An announcement on re-supply is expected in the next fortnight.

Ondansetron 4 mg ODT – stock shortage

We have been advised by Dr Reddy’s that stock of its brand of ondansetron dispersible tablets 4 mg (Dr Reddy’s) is in short supply. There are no supply issues for the dispersible tablets 8 mg (also Dr Reddy’s brand). Dr Reddy’s expects to be able to re-supply from early November 2013. Patients may need to see their prescriber if stock is unavailable.


6

Pharmaceutical Schedule - Update News

Prednisone tab 1 mg – re-supply

The short supply of Apotex brand of prednisone tablets 1 mg (Apo-Prednisone S29), p’code 2443066 has been resolved. Apotex expect to be able to re-supply the market during the week beginning 14 October 2013.

News in brief

• New pack size of 850 g for Ensure oral feed powder to be listed from 1 November 2013. • Brand name change for levodopa 50 mg with benserazide 12.5 mg tablets from Madopar Dispersible to Madopar Rapid. • Methotrexate (Methotrexate Sandoz) inj 7.5 mg, 10 mg 15 mg, 20 mg, 25 mg and 30 mg prefilled syringe – new listing. • From 1 November, the presentation description for salbutamol oral liquid (Salapin and Ventolin) will change from 2 mg per 5 ml to 400 mcg per ml.


Tender News

Sole Subsidised Supply changes – effective 1 December 2013

Chemical Name Dextrose with electrolytes Gemfibrozil Lamivudine Pindolol Pindolol Pindolol Presentation; Pack size Soln with electrolytes; 1,000 ml OP Tab 600 mg; 60 tab Oral liq 10 mg per ml; 240 ml OP Tab 5 mg; 100 tab Tab 10 mg; 100 tab Tab 15 mg; 100 tab Sole Subsidised Supply brand (and supplier) Pedialyte-Bubblegum (Abbott) Lipazil (Douglas) 3TC (GlaxoSmithKline) Apo-Pindolol (Apotex) Apo-Pindolol (Apotex) Apo-Pindolol (Apotex)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for future implementation 1 December 2013 • Amendment to Practitioner’s Supply Order rules relating to certain antibiotics for rheumatic fever prevention. • Montelukast (Singulair) tab 4 mg, 5 mg and 10 mg - amend Special Authority criteria.

7


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Abacavir sulphate Acarbose Acetazolamide Acetylcysteine Aciclovir Allopurinol Amantadine hydrochloride Aminophylline Amiodarone hydrochloride Amisulpride Amitriptyline Amlodipine Amoxycillin Amoxycillin clavulanate

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg and 100 mg Tab 250 mg Inj 200 mg per ml, 10 ml Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Inj 25 mg per ml, 10 ml Inj 50 mg per ml, 3 ml ampoule Oral liq 100 mg per ml Tab 100 mg, 200 mg & 400 mg Tab 10 mg Tab 25 mg & 50 mg Tab 2.5 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab 500 mg with potassium clavulanate 125 mg Crm Tab 50 mg & 100 mg Tab 10 mg, 20 mg, 40 mg & 80 mg Inj 600 mcg, 1 ml Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 1.2 mega u per 2.3 ml Inj 600 mg Eye drops 0.5% Eye drops 0.25%

Brand Name Expiry Date*

Ziagen Ziagen Accarb Diamox Martindale Acetylcysteine Lovir Apo-Allopurinol Symmetrel DBL Aminophylline Cordarone-X Solian Arrow-Amitriptyline Amitrip Apo-Amlodipine Apo-Amlodipine Ibiamox Augmentin Augmentin Curam Duo AFT Mylan Atenolol Zarator AstraZeneca Apo-Azithromycin Pacifen ArrowBendrofluazide Bicillin LA Sandoz Betoptic Betoptic S 2014 2014 2015 2015 2015 2015 2016 2014 2015 2014 2014 2014 2015 2014 2015 2016 2014 2014 2014 2016 2016 2014 2014 2014 2015

Aqueous cream Atenolol Atorvastatin Atropine sulphate Azithromycin Baclofen Bendrofluazide Benzathine benzylpenicillin Benzylpenicillin sodium (Penicillin G) Betaxolol hydrochloride

8

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Bezafibrate Bicalutamide Blood glucose diagnostic test meter Blood glucose diagnostic test strip Boceprevir Brimonidine tartrate Bupropion hydrochloride Cabergoline Calamine Calcitonin Calcium carbonate Calcium folinate Candesartan Carbomer Cefalexin monohydrate

Presentation

Tab 200 mg Tab long-acting 400 mg Tab 50 mg Meter with 50 lancets, a lancing device and 10 diagnostic test strips Blood glucose test strips Cap 200 mg Eye drops 0.2% Tab modified-release 150 mg Tab 0.5 mg Lotn, BP Inj 100 iu per ml, 1 ml Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 4 mg, 8 mg, 16 mg & 32 mg Ophthalmic gel 0.3%, 0.5 g Cap 500 mg Grans for oral liq 125 mg per 5 ml & 250 mg per 5 ml Inj 500 mg & 1 g Inj 750 mg Oral liq 1 mg per ml Tab 10 mg Eye oint 1% Eye drops 0.5% Mouthwash 0.2% Handrub 1% with ethanol 70% Soln 4% Nail-soln 8% Tab 0.5 mg, 2.5 mg & 5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 500 mg Tab 250 mg Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml

Brand Name Expiry Date*

Bezalip Bezalip Retard Bicalaccord CareSens N CareSens N POP CareSens II CareSens CareSens N Victrelis Arrow-Brimonidine Zyban Dostinex PSM Miacalcic Arrow-Calcium Calsource DBL Leucovorin Calcium Candestar Poly-Gel Cephalexin ABM Cefalexin Sandoz AFT Multichem Cetirizine - AFT Zetop Chlorsig Chlorafast healthE healthE Orion Apo-Ciclopirox Zapril Cipflox Arrow-Citalopram Apo-Clarithromycin Apo-Clarithromycin Clindamycin ABM Dalacin C 2015 2014 2015

2015 2016 2014 2016 2015 2015 2014 2014 2014 2015 2016 2016 2015 2014 2014 2014 2015 2015 2014 2015 2016 2014 2014 2014 2016

Cefazolin sodium Cefuroxime sodium Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate

Ciclopirox olamine Cilazapril Ciprofloxacin Citalopram hydrobromide Clarithromycin Clindamycin

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

9


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Clomiphene citrate Clomipramine hydrochloride Clonidine hydrochloride

Presentation

Tab 50 mg Tab 10 mg & 25 mg Tab 25 mcg Tab 150 mcg Inj 150 mcg per ml, 1 ml Crm 1% Tab 15 mg, 30 mg & 60 mg Tab 500 mcg Crm 10% Tab 50 mg Oral liq 100 mg per ml Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs Nasal spray 10 mcg per dose Tab 1 mg & 4 mg Eye oint 0.1%

Brand Name Expiry Date*

Serophene Apo-Clomipramine Clonidine BNM Catapres Clomazol PSM Colgout Itch-Soothe Nausicalm Neoral Siterone Ginet 84 Desmopressin-PH&T Douglas Maxidex Maxitrol Maxitrol 2016 2015 2015

Clotrimazole Codeine phosphate Colchicine Crotamiton Cyclizine hydrochloride Cyclosporin Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone

2014 2016 2016 2015 2015 2015 2015 2014 2014 2015 2014 2014

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dexamphetamine sulphate Dextrose Diclofenac sodium Tab 5 mg Inj 50%, 10 ml Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab 30 mg & 60 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 10 mg Tab 2 mg & 4 mg Tab 100 mg

PSM Biomed Apo-Diclo Diclax SR Voltaren Voltaren Ophtha Voltaren DHC Continus Apo-Diltiazem CD Dilzem Pytazen SR Laxofast 50 Laxofast 120 Prokinex Apo-Doxazosin Doxine

2015 2014 2015 2014

Dihydrocodeine tartrate Diltiazem hydrochloride

2016 2015

Dipyridamole Docusate sodium Domperidone Doxazosin mesylate Doxycycline hydrochloride

2014 2014 2015 2014 2014

10

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Emulsifying ointment Enoxaparin sodium Entacapone Ergometrine maleate Etidronate disodium Ethinyloestradiol Ethinyloestradiol with levonorgestrel

Presentation

Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Inj 500 mcg per ml, 1 ml Tab 200 mg Tab 10 mcg Tab 20 mcg with levonorgestrel 100 mcg & 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg & 7 inert tab Tab 25 mg Tab long-acting 5 mg & 10 mg Tab long-acting 2.5 mg Inj 50 mcg per ml, 2 ml & 10 ml Inj 300 mcg per 0.5 ml Inj 480 mcg per 0.5 ml Tab 5 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 250 mg & 500 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Eye drops 0.1% Crm 5% Metered aqueous nasal spray, 50 mcg per dose Tab 500 mg Tab 40 mg Oint 2% Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Suppos 3.6 g Aerosol spray 400 mcg per dose TDDS 5 mg & 10 mg Tab 600 mcg Tab 500 mcg, 1.5 mg & 5 mg Oral liq 2 mg per ml Inj 5 mg per ml, 1 ml

Brand Name Expiry Date*

AFT Clexane Entapone DBL Ergometrine Arrow-Etidronate NZ Medical and Scientific Ava 20 ED Ava 30 ED Aromasin Plendil ER Plendil ER Boucher and Muir Zarzio Zarzio Rex Medical AFT Staphlex Flucloxin Ozole Flucon Efudix Flixonase Hayfever & Allergy Urex Forte Diurin 40 Foban Pfizer Apo-Gliclazide Minidiab PSM Glytrin Nitroderm TTS Lycinate Serenace 2014 2015 2015

31/12/15

2014 2015 2015 2014 2015 2015 2014

Exemestane Felodopine Fentanyl Filgrastim Finasteride Flucloxacillin sodium

2014 2015 2014 2014 2015 2015 2015 2015 2016 2015 2014 2015 2015 2014

Fluconazole Fluorometholone Fluorouracil sodium Fluticasone propionate Furosemide Fusidic acid Gentamicin sulphate Gliclazide Glipizide Glycerol Glyceryl trinitrate

Haloperidol

2016

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

11


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Hydrocortisone

Presentation

Inj 100 mg vial Tab 5 mg & 20 mg Crm 1% Powder Rectal foam 10%, CFC-Free (14 applications) Lipocream 0.1% Milky emul 0.1% Oint 0.1% Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Inj 20 mg, 1 ml Tab 10 mg Tab 200 mg Tab long-acting 800 mg Crm 5% Tab 2.5 mg Nebuliser soln, 250 mcg per ml, 1 ml Nebuliser soln, 250 mcg per ml, 2 ml Inj 50 mg per ml, 2 ml Tab 100 mg Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Powder for oral soln Cap 100 mg Shampoo 2% Tab 100 mg Cap 15 mg & 30 mg Eye drops 50 mcg per ml Tab 2.5 mg Tab 1.5 mg Subdermal implant (2 x 75 mg rods) Inj 2% ampoule, 5 ml & 20 ml Viscous soln 2% Tab 5 mg, 10 mg & 20 mg

Brand Name Expiry Date*

Solu-Cortef Douglas Pharmacy Health ABM Colifoam Locoid Lipocream Locoid Crelo Locoid Locoid DP Lotn HC ABM Hydroxocobalamin Plaquenil Buscopan Gastrosoothe Arrowcare Brufen SR Aldara Dapa-Tabs Univent Ferrum H PSM Ismo 20 Corangin Oratane Konsyl-D Itrazole Sebizole Zetlam Solox Hysite Letraccord Postinor-1 Jadelle Lidocaine-Claris Xylocaine Viscous Arrow-Lisinopril 2016 2015 2014 2015 2015

Hydrocortisone acetate Hydrocortisone butyrate

Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hyoscine N-butylbromide Ibuprofen Imiquimod Indapamide Ipratropium bromide Iron polymaltose Isoniazid Isosorbide mononitrate Isotretinoin Ispaghula (psyllium) husk Itraconazole Ketoconazole Lamivudine Lansoprazole Latanoprost Letrozole Levonorgestrel Lidocaine [lignocaine] hydrochloride Lisinopril

2014 2015 2015 2014 2014 2014 2016 2016 2014 2015 2014 2015 2016 2016 2014 2014 2015 2015 2015 2016 31/12/13 2015 2014 2015

12

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Lithium carbonate Lodoxamide trometamol Losartan Losartan with hydrochlorothiazide Macrogol 400 and propylene glycol Mask for spacer device Mebendazole Mebeverine hydrochloride Medroxyprogesterone acetate Megestrol acetate Methotrexate Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Tab 250 mg & 400 mg Cap 250 mg Eye drops 0.1% Tab 12.5 mg, 25 mg, 50 mg & 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml Size 2 Tab 100 mg Tab 135 mg Tab 2.5 mg, 5 mg, 10 mg & 100 mg Inj 150 mg per ml, 1 ml syringe Tab 160 mg Inj 25 mg per ml, 2 ml & 20 ml Tab 4 mg & 100 mg Inj 40 mg per ml Inj 40 mg per ml with lignocaine 1 ml Enema 1 g per 100 ml Suppos 500 mg Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab 10 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg Inj 1 mg per ml, 5 ml Tab 50 mg & 100 mg Tab long-acting 200 mg Tab 50 mg Oral gel 20 mg per g Crm 2% Tab 30 mg & 45 mg

Brand Name Expiry Date*

Lithicarb FC Douglas Lomide Lostaar Arrow-Losartan & Hydroclorothiazide Systane Unit Dose EZ-fit Paediatric Mask De-Worm Colofac Provera Depo-Provera Apo-Megestrol Hospira Medrol Depo-Medrol Depo-Medrol with Lidocaine Pentasa Asacol Apotex Biodone Biodone Forte Biodone Extra Forte Solu-Medrol Pfizer Metamide Metoprolol-AFT CR Lopresor Lopresor Slow-Lopresor Puri-nethol Decozol Multichem Avanza 2015 2014 2014 2014 2014 2016 2015 2014 2014 2016 2015 2016 2015 2015 2015 2015 2014 2015 2015

Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol succinate Metoprolol tartrate

2015 2014 2015 2015

Mercaptopurine Miconazole Miconazole nitrate Mirtazapine

2016 2015 2014 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

13


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Mitomycin C Moclobemide Mometasone furoate Morphine hydrochloride Morphine sulphate

Presentation

Inj 5 mg vial Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml

Brand Name Expiry Date*

Arrow Apo-Moclobemide m-Mometasone RA-Morph Arrow-Morphine LA DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Hospira Naltraccord Naphcon Forte Apo-Nadolol Noflam 250 Noflam 500 AstraZeneca Nevirapine Alphapharm Habitrol Habitrol Habitrol Apo-Nicotinic Acid Noriday 28 Primolut N Arrow-Norfloxacin Norpress Nilstat Octreotide Max Rx 2014 2015 2014 2014 2016 2014 2014 2016 2015 2015 2015 2016 2014

Morphine tartrate Naltrexone hydrochloride Naphazoline hydrochloride Nadolol Naproxen Neostigmine Nevirapine Nicotine

Inj 80 mg per ml, 1.5 ml & 5 ml Tab 50 mg Eye drops 0.1% Tab 40 mg & 80 mg Tab 250 mg Tab 500 mg Inj 2.5 mg per ml, 1 ml Tab 200 mg Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 350 mcg Tab 5 mg Tab 400 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml Crm

2016 2016 2014 2015 2015 2014 2015 2014

Nicotinic acid Norethisterone Norfloxacin Nortriptyline hydrochloride Nystatin Octreotide (somatostatin analogue) Oil in water emulsion

healthE Fatty Cream

2015

14

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Omeprazole

Presentation

Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab 10 mg & 15 mg Oral liq 5 mg per ml Tab 5 mg Inj 50 mg per ml, 1 ml Inj 10 mg per ml, 1 ml & 2 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Inj 3 mg per ml, 10 ml; 6 mg per ml, 10 ml & 9 mg per ml, 10 ml Inj 40 mg Suppos 500 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Low range & normal range Inj 135 mcg prefilled syringe & inj 180 mcg prefilled syringe Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 Tab 0.25 mg & 1 mg Crm 5% Lotn 5% Tab 50 mg & 100 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

Brand Name Expiry Date*

Omezol Relief Midwest Dr Reddy’s Omeprazole Ox-Pam Apo-Oxybutynin OxyNorm Oxycodone Orion Syntometrine Pamidronate BNM Pantocid IV Paracare Parafast Ethics Paracetamol Paracare Double Strength Paracetamol + Codeine (Relieve) Breath-Alert Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax Lyderm A-Scabies PSM DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride PSM 2014 2014 2015 2014 2014

Oxazepam Oxybutynin Oxycodone hydrochloride Oxytocin Pamidronate disodium Pantoprazole Paracetamol

2014 2016 2015 2015 2014 2014 2015 2014

Paracetamol with codeine Peak flow meter Pegylated interferon alfa-2a Pegylated interferon alfa-2a

2014 2015 2017 2017

Pergolide Permethrin Pethidine hydrochloride

Phenobarbitone

Tab 15 mg & 30 mg

2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

15


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Pioglitazone Pizotifen Poloxamer Potassium chloride Pravastatin Procaine penicillin Promethazine hydrochloride Pyridostigmine bromide Pyridoxine hydrochloride Quinapril Quinapril with hydrochlorothiazide

Presentation

Tab 15 mg, 30 mg & 45 mg Tab 500 mcg Oral drops 10% Tab long-acting 600 mg Tab 20 mg & 40 mg Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg Tab 60 mg Tab 25 mg Tab 50 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 100 mg Tab orodispersible 10 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Tab 50 mg & 100 mg Tab 25 mg, 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml ampoule Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Eye drops 1 mg per ml, 10 ml OP 800 ml 230 ml (single patient)

Brand Name Expiry Date*

Pizaccord Sandomigran Coloxyl Span-K Cholvastin Cilicaine Allersoothe Allersoothe Mestinon PyridoxADE Apo-Pyridoxine Arrow-Quinapril Accuretic 10 Accuretic 20 Peptisoothe Arrow-Ranitidine Mycobutin Norvir Rizamelt ArrowRoxithromycin Asthalin Duolin 2014 2016 2015 2014 2015 2015 2015 2015 2015 2014 2015 2014 2014 2015 2014 2014 2015 2015

Ranitidine hydrochloride Rifabutin Ritonavir Rizatriptan Roxithromycin Salbutamol Salbutamol with ipratropium bromide Sertraline Sildenafil Simvastatin

Arrow-Sertraline Silagra Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg Biomed Micolette Hylo-Fresh Volumatic Space Chamber Plus

2016 2014 2014

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium hyaluronate Spacer device

2016 2016 2016 2015

16

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Spironolactone Sulphasalazine Sumatriptan Tamoxifen citrate Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Temozolomide Terazosin Terbinafine Testosterone cypionate Testosterone undecanoate Tetrabenazine Tetracosactrin Timolol maleate Tobramycin

Presentation

Tab 25 mg & 100 mg Tab 500 mg Tab EC 500 mg Tab 50 mg & 100 mg Inj 12 mg per ml, 0.5 ml cartridge Tab 20 mg Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Cap 5 mg, 20 mg, 100 mg & 250 mg Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Tab 25 mg Inj 250 mcg per ml, 1 ml ampoule Inj 1 mg per ml, 1 ml Eye drops 0.25% & 0.5% Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml Tab 100 mg Cap 50 mg Crm 0.5 mg per g Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Eye drops 0.5% & 1% Cap 250 mg Inj 500 mg Tab 40 mg & 80 mg Cap 100 mg & oral liq 10 mg per ml Tab 300 mg with lamivudine 150 mg Oint BP

Brand Name Expiry Date*

Spirotone Salazopyrin Salazopyrin EN Arrow-Sumatriptan Genox Pinetarsol 2016 2016 2016 2014 2014

Normison Temaccord Arrow Dr Reddy’s Terbinafine Depo-Testosterone Andriol Testocaps Motetis Synacthen Synacthen Depot Arrow-Timolol Tobrex Tobrex DBL Tobramycin Tasmar Arrow-Tramadol ReTrieve Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort Mydriacyl Ursosan Mylan Isoptin Retrovir Alphapharm Multichem

2014 2016 2016 2014 2014 2015 2016 2014 2014 2014

Tolcapone Tramadol hydrochloride Tretinoin Triamcinolone acetonide

2014 2014 2016 2014

Tropicamide Ursodeoxycholic acid Vancomycin hydrochloride Verapamil hydrochloride Zidovudine [AZT] Zidovudine [AZT] with lamivudine Zinc and castor oil

2014 2014 2014 2014 2016 2014 2014

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

17


Sole Subsidised Supply Products – cumulative to November 2013

Generic Name

Zinc sulphate

Presentation

Caps 137.4 mg (50 mg elemental)

Brand Name Expiry Date*

Zincaps 2014

November changes are in bold type

18

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 November 2013

39 69 LACTULOSE – Only on a prescription ❋ Oral liq 10 g per 15 ml ............................................................... 3.84 CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10% ...................................................... 6.50 500 ml ✔ Laevolac

1,000 g OP ✔ Pharmacy Health Sorbolene with Glycerin 90 50 50 ✔ Loxamine ✔ Onrex ✔ Onrex

124 131 137

PAROXETINE HYDROCHLORIDE ❋ Tab 20 mg ................................................................................ 4.32 ONDANSETRON ❋ Tab 4 mg .................................................................................. 5.51 ❋ Tab 8 mg .................................................................................. 6.19

ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency Tab 250 mcg ............................................................................ 2.50 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 mcg............................................................................. 3.25 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg .................................................................................. 5.00 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. METHOTREXATE ❋ Inj 7.5 mg prefilled syringe....................................................... 17.19 ❋ Inj 10 mg prefilled syringe........................................................ 17.25 ❋ Inj 15 mg prefilled syringe........................................................ 17.38 ❋ Inj 20 mg prefilled syringe........................................................ 17.50 ❋ Inj 25 mg prefilled syringe........................................................ 17.63 ❋ Inj 30 mg prefilled syringe........................................................ 17.75 SALBUTAMOL ‡ Oral liq 400 mcg per ml ............................................................ 2.06 1 1 1 1 1 1 150 ml

✔ Xanax ✔ Xanax ✔ Xanax

149 178 207

✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Ventolin ✔ Ensure

ORAL FEED (POWDER) – Special Authority see SA1228 – Hospital pharmacy [HP3] Powder (vanilla) ..................................................................... 13.00 850 g OP

Effective 1 October 2013

46 52 CLOPIDOGREL ❋ Tab 75 mg – For clopidogrel oral liquid formulation refer, page 189 .............................................................................. 5.48 ENALAPRIL MALEATE ❋ Tab 5 mg ................................................................................. 1.19 ❋ Tab 10 mg ............................................................................... 1.47 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 1.91 84 100 100 100 ✔ Arrow - Clopid ✔ Ethics Enalapril ✔ Ethics Enalapril ✔ Ethics Enalapril

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

19


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 October 2013 (continued)

61 79 119 HYDRALAZINE HYDROCHLORIDE ❋ Inj 20 mg ampoule .................................................................. 25.90 5 ✔ Apresoline s29 S29 ✔ Tamsulosin-Rex ✔ Rilutek

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy ❋ Cap 400 mcg .......................................................................... 13.51 100 RILUZOLE– Special Authority see SA1403 – Retail pharmacy – Wastage rule applies Tab 50 mg ............................................................................ 400.00 56

➽ SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and 3 The patient has not undergone a tracheostomy; and 4 The patient has not experienced respiratory failure; and 5 Any of the following: 5.1 The patient is ambulatory; or 5.2 The patient is able to use upper limbs; or 5.3 The patient is able to swallow. Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 The patient has not undergone a tracheostomy, and 2 The patient has not experienced respiratory failure; and 3 Any of the following: 3.1 The patient is ambulatory; or 3.2 The patient is able to use upper limbs; or 3.3 The patient is able to swallow. 123 MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 75 mg – wastage rule applies ........................................... 14.01 20 ✔ Ludiomil s29 S29 CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist – wastage rule applies ....................................................... 158.00 TAMOXIFEN CITRATE ❋ Tab 10 mg ............................................................................... 2.63 ❋ Tab 20 mg ............................................................................... 2.63 Note – these are new packsizes with new Pharmacodes. LORATADINE ❋ Tab 10 mg ................................................................................ 1.30

147

100 60 30

✔ Procytox S29 ✔ Genox ✔ Genox

160 176

100

✔ Lorafix

Effective 1 September 2013

25 MESALAZINE Modified release granules, 1 g ............................................... 141.72 120 g OP ✔ Pentasa

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

20

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2013 (continued)

82 87 TETRACOSACTRIN ❋ Inj 250 mcg per ml, 1 ml ampoule ........................................... 17.71 DESMOPRESSIN Tab 100 mcg – Special Authority see SA1401 – Retail pharmacy................................................................ 36.40 Tab 200 mcg – Special Authority see SA1401 – Retail pharmacy................................................................ 93.60 1 ✔ Synacthen

30 30

✔ Minirin ✔ Minirin

➽ SA1401 Special Authority for Subsidy Initial application (Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: 1. The patient has primary nocturnal enuresis; and 2. The nasal forms of desmopressin are contraindicated; and 3. An enuresis alarm is contraindicated. Initial application (Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: 1. The patient has cranial diabetes insipidus; and 2. The nasal forms of desmopressin are contraindicated Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. 98 BOCEPREVIR – Special Authority see SA1365 – Retail pharmacy – Wastage rule applies Cap 200 mg ....................................................................... 5,015.00 336 ✔ Victrelis ➽ SA1365 Special Authority for Subsidy Initial application — (chronic hepatitis C – genotype 1, first-line) from gastroenterologist, infectious disease physician or general physician Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has not received prior pegylated interferon treatment; and 3 Patient has IL-28B genotype CT or TT; and 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and 5 Patient is hepatitis C protease inhibitor treatment-naive; and 6 Maximum of 44 weeks therapy. Initial application — (chronic hepatitis C – genotype 1, second-line) from gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has received pegylated interferon treatment; and 3 Any of the following: 3.1. Patient was a responder relapser; or 3.2. Patient was a partial responder; or 3.3. Patient received pegylated interferon prior to 2004; and 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and 5 Maximum of 44 weeks therapy. Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count <100 x109 /l or Albumin <35 g/l. Note: the wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly. 113 RISEDRONATE SODIUM Tab 35 mg ............................................................................... 4.00 4 ✔ Risedronate Sandoz

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

21


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2013 (continued)

123 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency – Wastage rule applies Tab 10 mg ................................................................................ 6.58 60 ✔ Tofranil S29 S29 THIOTEPA – PCT only – Specialist Inj 15 mg ............................................................................. CBS PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN ❋ Eye oint with soft white paraffin ................................................. 3.63 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Acetec is 2445441

148

1 3.5 g OP 1 fee

✔ Tepadina S29 ✔ Refresh Night Time ✔ BSF Acetec

186 187

202

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (strawberry) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (vanilla) .......................................................................... 1.07 200 ml OP ✔ Pediasure Note – the packaging has changed to Recloseable Plastic Bottle (RPB) with new Pharmacodes. PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (vanilla) .......................................................................... 1.34 250 ml OP ✔ Pediasure

202

Effective 12 August 2013

52 ENALAPRIL MALEATE ❋ Tab 5 mg ................................................................................. 0.36 5.94 ❋ Tab 10 mg ............................................................................... 0.44 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 30 500 30 500 30 ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

22

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions, Chemical Names and Presentations

Effective 1 November 2013

61 101 HYDRALAZINE HYDROCHLORIDE (remove the S29 symbol) ❋ Inj 20 mg ampoule .................................................................. 25.90 VALGANCICLOVIR – Special Authority see SA14041274 – Retail pharmacy Tab 450 mg ...................................................................... 3,000.00 5 60 ✔ Apresoline s29 S29 ✔ Valcyte

➽ SA14041274 Special Authority for Subsidy Initial application - (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis Renewal application - (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin Initial application - (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis Renewal - (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis. Initial application - (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1. Patient has undergone a lung transplant; and 2. Either: 2.1. The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2. The recipient is cytomegalovirus positive. Initial application - (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1. Patient is immunocompromised; and 2. Any of the following 2.1. Patient has cytomegalovirus syndrome or tissue invasive disease, or 2.2. Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3. Patient has cytomegalovirus retinitis Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions Renewal application - (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1. Patient is immunocompromised; and 2. Any of the following 2.1. Patient has cytomegalovirus syndrome or tissue invasive disease, or 2.2. Patient has rapidly rising plasma CMV DNA in absence of disease; or continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

23


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 November 2013 (continued)

continued... 2.3. Patient has cytomegalovirus retinitis Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions 123 MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency (remove the S29 symbol) Tab 75 mg – wastage rule applies ........................................... 14.01 20 ✔ Ludiomil s29 S29 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency – wastage rule applies (remove the S29 symbol) Tab 10 mg ............................................................................... 6.58 60 ✔ Tofranil s29 S29 SALBUTAMOL (amendment to presentation description) ‡ Oral liq 2 mg per 5 ml 400 mcg per ml ....................................... 1.99 2.06 150 ml ✔ Salapin ✔ Ventolin

123

178

Effective 1 October 2013

52 ENALAPRIL MALEATE (addition of STAT dispensing) ❋ Tab 5 mg .................................................................................. 0.36 1.07 1.19 5.94 ❋ Tab 10 mg ................................................................................ 0.44 1.32 1.47 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 1.72 1.91 Note: the removal of the stat symbol will be temporary due to a stock recall 30 90 100 500 30 90 100 500 30 90 100 ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril ✔ Acetec ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril ✔ Acetec ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril

52

PERINDOPRIL (removal of subsidy by endorsement) From 1 August 2013 to 30 September 2013 the Coversyl brand of perindopril will be funded by Endorsement to the level of the ex-manufacturer price listed in the Schedule for patients who were previously accessing the higher subsidy by endorsement for perindopril prior to 1 May 2013. ❋ Tab 2 mg – Higher subsidy of up to $18.50 per 30 tab with Endorsement ......................................................................... 3.75 30 ✔ Apo-Perindopril (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of up to $25.00 per 30 tab with Endorsement ......................................................................... 4.80 30 ✔ Apo-Perindopril (25.00) Coversyl ZOLEDRONIC ACID – Special Authority see SA1187 – Retail pharmacy (addition of OP) Soln for infusion 5 mg in 100 ml ............................................ 600.00 100 ml OP ✔ Aclasta

115

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

24

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 October 2013 (continued)

122 OXYCODONE HYDROCHLORIDE (amendment to presentation description) a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Cap immediate-release 5 mg .................................................. 2.83 Cap immediate-release 10 mg ................................................ 5.58 Cap immediate-release 20 mg ................................................ 9.77

20 20 20

✔ OxyNorm ✔ OxyNorm ✔ OxyNorm

130

HYOSCINE HYDROBROMIDE HYOSCINE (SCOPOLAMINE) – Special Authority see SA1387 – Retail pharmacy (change to chemical name) Patch 1.5 mg .......................................................................... 11.95 2 ✔ Scopoderm TTS

Effective 1 September 2013

52 ENALAPRIL MALEATE – Brand switch fee payable (Pharmacode 2445441) - see page 187 for details Tab 5 mg .................................................................................. 0.36 30 ✔ Acetec 1.07 90 ✔ m-Enalapril 5.94 500 ✔ Acetec Tab 10 mg ................................................................................ 0.44 30 ✔ Acetec 1.32 90 ✔ m-Enalapril 7.33 500 ✔ Acetec Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 30 ✔ Acetec 1.72 90 ✔ m-Enalapril Note: the removal of the stat symbol will be temporary due to a stock recall TETRACOSACTRIN (amendment to presentation) ❋ Inj 250 mcg per ml, 1 ml ampoule .......................................... 17.71 177.18 1 10 ✔ Synacthen ✔ Synacthen

82 106

Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment 1) Diagnosis • Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or • PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or • Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following. Exclusion Criteria 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 109) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage continued... ❋ Three months or six months, as applicable, dispensed all-at-once

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

25


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

continued... The current recommended dosage is 3 million units of interferon alfa-2a alpha-2a or interferon alpha-2b alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months) Exit Criteria The patient’s response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pretreatment ALlevel at this stage. 107 INTERFERON ALFA-2A ALPHA-2A – PCT – Retail pharmacy-Specialist (amendment to chemical name) a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 3 m iu prefilled syringe ....................................................... 31.32 1 ✔ Roferon-A Inj 6 m iu prefilled syringe ....................................................... 62.64 1 ✔ Roferon-A Inj 9 m iu prefilled syringe ....................................................... 93.96 1 ✔ Roferon-A INTERFERON ALFA-2B ALPHA-2B – PCT – Retail pharmacy-Specialist (amendment to chemical name) a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 18 m iu, 1.2 ml multidose pen .......................................... 187.92 1 ✔ Intron-A Inj 30 m iu, 1.2 ml multidose pen .......................................... 313.20 1 ✔ Intron-A Inj 60 m iu, 1.2 ml multidose pen .......................................... 626.40 1 ✔ Intron-A PEGYLATED INTERFERON ALFA-2A ALPHA-2A – Special Authority see SA14001365 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe ............................................... 1,448.00 4 Inj 180 mcg prefilled syringe .................................................. 900.00 4 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ......................................................... 1,159.84 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ........................................................ 1,290.00 1 OP

107

107

✔ Pegasys ✔ Pegasys ✔ Pegasys RBV Combination Pack ✔ Pegasys RBV Combination Pack

➽ SA14001365 Special Authority for Subsidy Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both: 1. Any of the following: 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and 2. Maximum of 48 weeks therapy. Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml. Renewal application — (Chronic hepatitis C – genotype 1 infection) from gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for patients meeting the following continued... criteria: Patients pay a manufacturer’s surcharge when S29 Unapproved medicine supplied under Section 29 the Manufacturer’s Price is greater than the Subsidy ‡ safety cap reimbursed Sole Subsidised Supply

26


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

continued... All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has had previous treatment with pegylated interferon and ribavirin; and 3 Either: 3.1 Patient has responder relapsed; or 3.2 Patient was a partial responder; and 4 Patient is to be treated in combination with boceprevir; and 5 Maximum of 48 weeks therapy. Initial application (Chronic Hepatitis C – genotype 1 infection treatment more than 4 years prior) from a gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for patients meeting the following criteria: All of the following 1. Patient has chronic hepatitis C, genotype 1; and 2. Patient has had previous treatment with pegylated interferon and ribavirin; and 3. Any of the following: 3.1. Patient has responder relapsed; or 3.2. Patient was a partial responder; or 3.3. Patient received interferon treatment prior to 2004; and 4. Patient is to be treated in combination with boceprevir; and 5. Maximum of 48 weeks therapy. Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1. Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2. Maximum of 6 months therapy. Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B treatment-naive; and 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/ml; and 5 Either: 5.1 HBeAg positive; or 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and 6 Compensated liver disease; and 7 No continuing alcohol abuse or intravenous drug use; and 8 Not co-infected with HCV, HIV or HDV; and 9 Neither ALT nor AST > 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylated interferon; and 11 Maximum of 48 weeks therapy. Notes: Approved dose is 180 mcg once weekly. The recommended dose of Pegylated Interferon-alpha 2a Interferon alfa-2a is 180 mcg once weekly. In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferonalpha 2a Interferon alfa-2a dose should be reduced to 135 mcg once weekly. In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. Pegylated Interferon-alpha 2a Interferon alfa-2a is not approved for use in children.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

27


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

125 VENLAFAXINE – Special Authority see SA1061 – Retail pharmacy Tab 37.5 mg ............................................................................ 5.06 Tab 75 mg ................................................................................ 6.44 Tab 150 mg .............................................................................. 8.86 Tab 225 mg ............................................................................ 14.34 Cap 37.5 mg – Special Authority see SA1061 – Retail pharmacy ................................................................ 8.71 Cap 75 mg – Special Authority see SA1061 – Retail pharmacy .............................................................. 17.42 Cap 150 mg – Special Authority see SA1061 – Retail pharmacy .............................................................. 21.35 RISPERIDONE – Special Authority see SA0927 – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Tab orodispersible Orally-disintegrating tablets 0.5 mg ........... 21.42 Tab orodispersible Orally-disintegrating tablets 1 mg ............. 42.84 Tab orodispersible Orally-disintegrating tablets 2 mg ............. 85.71 CYTARABINE Inj 100 mg 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ..................................... 55.00 80.00 Inj 1 g 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .................................................. 8.83 42.65 Inj 2 g 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 17.65 34.47 28 28 28 28 28 28 28 ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Efexor XR ✔ Efexor XR ✔ Efexor XR

136

28 28 28

✔ Risperdal Quicklet ✔ Risperdal Quicklet ✔ Risperdal Quicklet

148

5 1 1

✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne

204

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 0.75 KCAL/ML – Special Authority see SA1196 – Hospital pharmacy [HP3] Liquid ........................................................................................ 4.00 500 ml OP ✔ Nutrini Low Energy Multi Fibre

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

28

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 November 2013

137 ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency ( subsidy) Tab 250 mcg............................................................................. 2.50 50 ✔ Arrow-Alprazolam ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg ................................................................................. 5.00 50 ✔ Arrow-Alprazolam ‡ Safety cap for extemporaneously compounded oral liquid preparations. MYCOPHENOLATE MOFETIL - Special Authority see SA1041 – Retail pharmacy ( subsidy) Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ............................................................................ 25.00 50 ✔ Myaccord (60.00) Ceptolate Cap 250 mg ............................................................................ 12.50 (30.00) 25.00 50 100 Ceptolate ✔ Myaccord

161

Effective 1 October 2013

78 88 122 CLOTRIMAZOLE ❋ Vaginal crm 1% with applicators ( subsidy) .............................. 1.45 ❋ Vaginal crm 2% with applicators ( subsidy).............................. 2.20 CEFACLOR MONOHYDRATE ( subsidy) Cap 250 mg ............................................................................ 26.00 OXYCODONE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 10 mg .................................................... 6.75 (11.14) Tab controlled-release 20 mg ................................................. 11.50 (18.93) Tab controlled-release 40 mg ................................................. 18.50 (33.29) Tab controlled-release 80 mg .................................................. 34.00 (58.03) 35 g OP 20 g OP 100 ✔ Clomazol ✔ Clomazol ✔ Ranbaxy-Cefaclor

20 OxyContin 20 OxyContin 20 OxyContin 20 OxyContin

Effective 1 September 2013

42 VITAMIN B COMPLEX ( subsidy) ❋ Tab, strong, BPC ....................................................................... 4.30 500 ✔ B-PlexADE ✔ Bplex

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

29


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2013 (continued)

42 ASCORBIC ACID ( subsidy) a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg .............................................................................. 7.00 VITAMINS ( subsidy) ❋ Tab (BPC cap strength) ............................................................. 7.60 POTASSIUM IODATE ( subsidy) ❋ Tab 256 mcg (150 mcg elemental iodine) ................................. 6.53 DEXTROSE WITH ELECTROLYTES ( subsidy) Soln with electrolytes ................................................................ 6.55 PINDOLOL ( subsidy) ❋ Tab 5 mg ................................................................................. 9.72 ❋ Tab 10 mg ............................................................................ 15.62 ❋ Tab 15 mg ............................................................................. 23.46 GEMFIBROZIL ( subsidy) ❋ Tab 600 mg ............................................................................ 17.60

42 43 51

500

✔ Vitala-C ✔ Cvite ✔ MultiADE ✔ Mvite ✔ NeuroKare

1,000

90

1,000 ml OP ✔ Pedialyte – Bubblegum 100 100 100 60 ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Lipazil

56 59 105 107

LAMIVUDINE – Special Authority see SA1364 – Retail pharmacy ( subsidy) Oral liq 10 mg per ml ............................................................. 102.50 240 ml OP ✔ 3TC PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1400 – Retail pharmacy ( subsidy) See prescribing guideline Inj 180 mcg prefilled syringe .................................................. 900.00 4 ✔ Pegasys Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ............................................................................ 1,159.84 1 OP ✔ Pegasys RBV Combination Pack Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ........................................................................... 1,290.00 1 OP ✔ Pegasys RBV Combination Pack LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ( subsidy) Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO ............ 17.50 (35.00) Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO ............ 12.00 (20.00) VENLAFAXINE ( subsidy) Tab 37.5 mg ............................................................................ 5.06 Tab 75 mg ................................................................................ 6.44 Tab 150 mg ............................................................................. 8.86 Tab 225 mg ............................................................................ 14.34 50 Xylocaine 5 Xylocaine 28 28 28 28 ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR

119

125

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

30

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2013 (continued)

148 CYTARABINE ( subsidy) Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ................................................ 55.00 Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .................................................. 8.83 Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 17.65 Inj 1 mg for ECP – PCT only – Specialist ................................... 0.11 Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.......................................................................... 11.00

5 1 1 10 mg

✔ Pfizer ✔ Pfizer ✔ Pfizer ✔ Baxter

100 mg OP ✔ Baxter

161

MYCOPHENOLATE MOFETIL – Special Authority see SA1041 – Retail pharmacy ( subsidy) Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ........................................................................... 25.00 50 ✔ Cellcept Cap 250 mg ........................................................................... 25.00 100 ✔ Cellcept

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

31


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 November 2013

14 “Pharmaceutical” means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I H of the Schedule.

Effective 1 September 2013

15 “Specialist”, in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below: a) i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the prescription in the course of practising in that area of medicine; and or ii) the doctor’s vocational scope of practice is one of those listed below: — anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology; or b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of medicine; or c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine; or d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so. 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference: a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand. 3.3.2 If a Community Pharmaceutical is either: a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply,or c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule. and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

18

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

32


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules - effective 1 September 2013 (continued)

continued... a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

Changes to Brand Name

Effective 1 November 2013

116 BENZBROMARONE – Special Authority see SA1319 – Retail pharmacy Tab 100 mg ............................................................................ 45.00 100 ✔ Benzbromaron Benzbromaron AL 100 S29 ✔ Madopar Dispersible Madopar Rapid

118

LEVODOPA WITH BENSERAZIDE ❋ Tab dispersible 50 mg with benserazide 12.5 mg ..................... 10.00

100

Changes to Section I

Effective 1 October 2013

225 HEPATITIS A VACCINE – Hospital pharmacy [Xpharm] Children, aged 1–4 years inclusive who reside in Ashburton district; or Children, aged 1–9 years inclusive, residing in Ashburton; or Children, aged 1–9 years inclusive, who attend a preschool or school in Ashburton; or Children, aged older than 9 years, who attend a school with children aged 9 years old or less, in Ashburton Inj ............................................................................................. 0.00 1 ✔ Havrix Junior

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

33


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 November 2013

181 212 SODIUM CROMOGLYCATE Nasal spray, 4% ..................................................................... 15.85 22 ml OP ✔ Rex

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3] Sachets (tropical) .................................................................. 324.00 30 ✔ Phlexy 10

Effective 1 October 2013

46 58 65 SODIUM TETRADECYL SULPHATE ❋ Inj 0.5% 2 ml .......................................................................... 23.20 (51.00) ❋ Inj 1% 2 ml ............................................................................. 25.00 (55.00) CLONIDINE HYDROCHLORIDE ❋ Tab 25 mcg............................................................................. 13.47 CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail soln 8% ........................................................................... 19.85 LEVONORGESTREL ❋ Tab 750 mcg ............................................................................ 3.50 ETHINYLOESTRADIOL WITH DESOGESTREL ❋ Tab 20 mcg with desogestrel 150 mcg ..................................... 6.62 (16.50) a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO ❋ Tab 30 mcg with desogestrel 150 mcg ..................................... 6.62 (16.50) a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO 5 Fibro-vein 5 Fibro-vein 100 ✔ Dixarit

3 g OP 2 63

✔ Batrafen ✔ Next Choice

78 76

Mercilon 21 63 Marvelon 21

88

CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 1 g .................................................................................... 55.00 5 ✔ Mayne

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

34

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 October 2013 (continued)

88 CEFUROXIME SODIUM Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement ....................................................... 20.97 10 ✔ Mayne Waiver by endorsement must state that the prescription is for dialysis or cystic fibrosis patient. Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorsement .................................................... 2.65 1 ✔ Mylan 4.04 ✔ Zinacef Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. FUSIDIC ACID Inj 500 mg sodium fusidate per 10 ml – Retail pharmacySpecialist – Subsidy by endorsement ................................... 12.87 1 (17.80) Fucidin Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO .............. 13.80 Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO ............ 12.00 50 5 ✔ Xylocaine ✔ Xylocaine

92

119

130

SUMATRIPTAN Tab 50 mg ............................................................................... 1.19 4 ✔ Arrow-Sumatriptan Tab 100 mg ............................................................................. 1.10 4 ✔ Arrow-Sumatriptan Note – Arrow-Sumatriptan tab 50 mg and 100 mg in 100 tab pack size remains subsidised. HOMATROPINE HYDROBROMIDE ❋ Eye drops 2% ........................................................................... 7.18 PHARMACY SERVICES ❋ Brand switch fee ....................................................................... 4.33 15 ml OP 1 fee ✔ Isopto Homatropine ✔ BSF Arrow-Quinapril

185 187

Effective 1 September 2013

31 32 107 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g × 12.7 mm ..................................................................... 10.50 100 ✔ ABM

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle ........................... 13.00 100 ✔ ABM ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle ........................... 13.00 100 ✔ ABM ❋ Syringe 0.5 ml with 31 g × 8 mm needle ................................ 13.00 100 ✔ ABM PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1365 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe .................................................. 362.00 1 ✔ Pegasys Inj 180 mcg prefilled syringe ................................................. 450.00 1 ✔ Pegasys FAT SUPPLEMENT – Special Authority see SA1374 – Hospital pharmacy [HP3] Oil ........................................................................................... 28.73 250 ml OP ✔ Liquigen ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Standard RTH ❋ Three months or six months, as applicable, dispensed all-at-once

199 207

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

35


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 September 2013 (continued)

207 ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Multi Fibre

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

36

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 December 2013

39 MACROGOL 3350 – Special Authority see SA0891 – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per prescription ......................................................................... 18.14 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Acetec is 2445441

30 1 fee

✔ Movicol ✔ BSF Acetec

187

Effective 1 January 2014

59 CHLORTALIDONE [CHLORTHALIDONE] ❋ Tab 25 mg ................................................................................ 4.80 30 Note – The delist date has been extended from 1 October 2013 to 1 January 2014. ✔ Igroton S29

Effective 1 February 2014

161 MYCOPHENOLATE MOFETIL – Special Authority see SA1041 – Retail pharmacy Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ............................................................................ 25.00 50 ✔ Myaccord (60.00) Ceptolate Cap 250 mg ............................................................................ 12.50 (30.00) 25.00 50 100 Ceptolate ✔ Myaccord

Effective 1 March 2014

77 NORETHISTERONE WITH MESTRANOL ❋ Tab 1 mg with mestranol 50 mcg and 7 inert tab........................ 6.62 (13.80) a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 b) Up to 84 tab available on a PSO PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN] Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO......... 315.00 AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg – For azathioprine oral liquid formulation refer, page 189 ............................................................................. 18.45 PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN ❋ Eye oint with soft white paraffin ................................................. 3.63 84 Norinyl-1/28

90 161 186 202

10

✔ Bicillin LA

100 3.5 g OP

✔ Imuran ✔ Lacri-Lube

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (strawberry) ................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (vanilla) .......................................................................... 1.07 200 ml O ✔ Pediasure 1.27 237 ml OP ✔ Pediasure Note – Replacement Pediasure packs were listed 1 September 2013. ❋ Three months or six months, as applicable, dispensed all-at-once

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

37


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 April 2014

131 ONDANSETRON ❋ Tab disp 4 mg .......................................................................... 0.68 ✔ Dr Reddy’s Ondansetron Note – Dr Reddy's Ondansetron tab dispersible 4 mg in the 100 pack size remains subsidised. CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist........................ 25.71 BUDESONIDE Powder for inhalation, 200 mcg per dose ................................ 15.20 Powder for inhalation, 400 mcg per dose ................................ 25.60 50 ✔ Cycloblastin 4

147 177

200 dose OP ✔ Budenocort 200 dose OP ✔ Budenocort

Effective 1 May 2014

52 86 ENALAPRIL MALEATE ❋ Tab 5 mg .................................................................................. 1.07 ❋ Tab 10 mg ............................................................................... 1.32 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189................................................................................... 1.72 90 90 90 ✔ m-Enalapril ✔ m-Enalapril ✔ m-Enalapril ✔ Synthroid ✔ Synthroid

LEVOTHYROXINE ❋ Tab 25 mcg ............................................................................ 43.24 1,000 ‡ Safety cap for extemporaneously compounded oral liquid preparations. ❋ Tab 50 mcg ............................................................................ 45.00 1,000 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Note – Synthroid in the 90 tablet pack size remain subsidised. METHOTREXATE ❋ Inj 25 mg per ml, 40 ml – PCT – Retail pharmacy - Specialist ............................................. 25.00

149

1

✔ DBL Methotrexate

S29

207

ORAL FEED (POWDER) – Special Authority see SA1228 – Hospital pharmacy [HP3] Powder (vanilla) ..................................................................... 13.00 900 g OP

✔ Ensure

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

38

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Index

Pharmaceuticals and brands Symbols 3TC ................................................................... 30 A Acetec ................................................... 22, 24, 25 Aclasta .............................................................. 24 Alprazolam ................................................... 19, 29 Aminoacid formula without phenylalanine ........... 34 Apo-Perindopril .................................................. 24 Apo-Pindolol ...................................................... 30 Apresoline s29 ............................................. 20, 23 Arrow-Alprazolam .............................................. 29 Arrow - Clopid.................................................... 19 Arrow-Sumatriptan ............................................. 35 Arrow-Venlafaxine XR................................... 28, 30 Ascorbic acid ..................................................... 30 Azathioprine ....................................................... 37 B Batrafen ............................................................. 34 Benzbromaron ................................................... 33 Benzbromaron AL 100 ....................................... 33 Benzbromarone .................................................. 33 Bicillin LA........................................................... 37 Boceprevir ......................................................... 21 Bplex ................................................................. 29 B-PlexADE ......................................................... 29 BSF Acetec .................................................. 22, 37 BSF Arrow-Quinapril ........................................... 35 Budenocort ........................................................ 38 Budesonide ........................................................ 38 C Cefaclor monohydrate ........................................ 29 Cefoxitin sodium ................................................ 34 Cefuroxime sodium ............................................ 35 Cellcept ............................................................. 31 Ceptolate ..................................................... 29, 37 Cetomacrogol with glycerol ................................ 19 Chlortalidone [chlorthalidone] ............................. 37 Ciclopirox olamine.............................................. 34 Clomazol............................................................ 29 Clonidine hydrochloride ...................................... 34 Clopidogrel ........................................................ 19 Clotrimazole ....................................................... 29 Coversyl ............................................................ 24 Cvite .................................................................. 30 Cycloblastin ....................................................... 38 Cyclophosphamide ...................................... 20, 38 Cytarabine ................................................... 28, 31 D DBL Methotrexate............................................... 38 Dr Reddy’s Ondansetron .................................... 38 Desmopressin .................................................... 21 Dextrose with electrolytes................................... 30 Dixarit ................................................................ 34 E Efexor XR ........................................................... 28 Efexor XR ........................................................... 28 Enalapril maleate ........................ 19, 22, 24, 25, 38 Ensure ......................................................... 19, 38 Enteral feed 1kcal/ml .......................................... 35 Enteral feed with fibre 1 kcal/ml .......................... 36 Ethics Enalapril ............................................ 19, 24 Ethinyloestradiol with desogestrel ....................... 34 F Fat supplement .................................................. 35 Fibro-vein........................................................... 34 Fucidin ............................................................... 35 Fusidic acid........................................................ 35 G Gemfibrozil ........................................................ 30 Genox ................................................................ 20 H Havrix Junior ...................................................... 33 Hepatitis A vaccine............................................. 33 Homatropine hydrobromide ................................ 35 Hydralazine hydrochloride ............................ 20, 23 Hyoscine (scopolamine)..................................... 25 Hyoscine hydrobromide ..................................... 25 I Igroton ............................................................... 37 Imuran ............................................................... 37 Insulin pen needles............................................. 35 Insulin syringes, disposable with attached needle 35 Interferon alfa-2a................................................ 26 Interferon alfa-2b ............................................... 26 Interferon alpha-2a ............................................. 26 interferon alpha-2b ............................................. 26 Imipramine hydrochloride ............................. 22, 24 Intron-A ............................................................. 26 Isopto Homatropine ............................................ 35 L Lacri-Lube ......................................................... 37 Lactulose ........................................................... 19 Laevolac ............................................................ 19 Lamivudine ........................................................ 30 Levodopa with benserazide ................................ 33 Levonorgestrel ................................................... 34 Levothyroxine .................................................... 38 Lidocaine [lignocaine] hydrochloride ............ 30, 35 Lipazil ................................................................ 30 Liquigen ............................................................. 35 Lorafix ............................................................... 20 Loratadine.......................................................... 20

39


Index

Pharmaceuticals and brands Loxamine ........................................................... 19 Ludiomil s29 ...................................................... 20 M Macrogol 3350 .................................................. 37 Madopar Dispersible .......................................... 33 Madopar Rapid .................................................. 33 Maprotiline hydrochloride ............................. 20, 24 Marvelon 21....................................................... 34 m-Enalapril ............................................ 24, 25, 38 Mercilon 21 ....................................................... 34 Mesalazine ......................................................... 20 Methotrexate ................................................ 19, 38 Methotrexate Sandoz .......................................... 19 Minirin ............................................................... 21 Movicol.............................................................. 37 MultiADE............................................................ 30 Mvite ................................................................. 30 Myaccord .................................................... 29, 37 Mycophenolate mofetil ........................... 29, 31, 37 N NeuroKare.......................................................... 30 Next Choice ....................................................... 34 Norethisterone with mestranol ............................ 37 Norinyl-1/28 ...................................................... 37 Nutrini Low Energy Multi Fibre ............................ 28 Nutrison Multi Fibre ............................................ 36 Nutrison Standard RTH....................................... 35 O Ondansetron ................................................ 19, 38 Onrex ................................................................. 19 Oral feed (powder) ....................................... 19, 38 Oxycodone hydrochloride ............................. 25, 29 OxyContin .......................................................... 29 OxyNorm ........................................................... 25 P Paediatric enteral feed with fibre 0.75 Kcal/ml..... 28 Paediatric enteral feed with fibre 0.76 kcal/ml ..... 28 Paediatric oral feed 1kcal/ml......................... 22, 37 Paraffin liquid with soft white paraffin ........... 22, 37 Paroxetine hydrochloride .................................... 19 Pedialyte – Bubblegum ....................................... 30 Pediasure..................................................... 22, 37 Pegasys................................................. 26, 30, 35 Pegasys RBV Combination Pack .................. 26, 30 Pegylated interferon alfa-2a .................... 26, 30, 35 Pegylated interferon alpha-2a ............................. 26 Penicillin g benzathine [benzathine benzylpenicillin] ............................ 37 Pentasa ............................................................. 20 Perindopril ......................................................... 24 Pharmacy Health Sorbolene with Glycerin ........... 19 Pharmacy services................................. 22, 35, 37 Phlexy 10........................................................... 34 Pindolol ............................................................. 30 Potassium iodate ............................................... 30 Procytox ............................................................ 20 R Ranbaxy-Cefaclor............................................... 29 Refresh Night Time ............................................ 22 Rilutek ............................................................... 20 Riluzole .............................................................. 20 Risedronate Sandoz ........................................... 21 Risedronate sodium ........................................... 21 Risperdal Quicklet .............................................. 28 Risperidone........................................................ 28 Roferon-A .......................................................... 26 S Salapin .............................................................. 24 Salbutamol................................................... 19, 24 Scopoderm TTS ................................................. 25 Sodium cromoglycate ........................................ 34 Sodium tetradecyl sulphate ................................ 34 Sumatriptan ....................................................... 35 Synacthen.................................................... 21, 25 Synthroid ........................................................... 38 T Tamoxifen citrate................................................ 20 Tamsulosin hydrochloride .................................. 20 Tamsulosin-Rex ................................................. 20 Tepadina ............................................................ 22 Tetracosactrin .............................................. 21, 25 Thiotepa............................................................. 22 Tofranil s29 ....................................................... 24 Tofranil S29 ....................................................... 22 V Valcyte............................................................... 23 Valganciclovir .................................................... 23 Venlafaxine .................................................. 28, 30 Ventolin ....................................................... 19, 24 Victrelis.............................................................. 21 Vitala-C .............................................................. 30 Vitamin B complex ............................................. 29 Vitamins ............................................................ 30 X Xanax................................................................. 19 Xylocaine ..................................................... 30, 35 Z Zinacef ............................................................... 35 Zoledronic acid .................................................. 24

40


Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 November 2013

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 November 2013 Cumulative for September, October and November 2013 Contents Summary of PHARMAC decisions effective 1 November 2013 ….. 3 Have a problem with a medicine or medical device we…

Page 1

icon

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.